REG - Aptamer Group PLC - Notification of dealings by a director/PDMR

AptamerAnnouncement

09/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250909:nRSI4893Ya&default-theme=true

RNS Number : 4893Y  Aptamer Group PLC  09 September 2025

 

9 September 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notification of dealings by a director/PDMR

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, today
announces that Dr Adam Hargreaves, Non-Executive Chairman, on 8 September 2025
purchased 5,000,000 ordinary shares of £0.001 each ("Ordinary Shares") in the
Company at a price of 1 pence per Ordinary Share, through Pathcelerate
Limited.

 

Following this transaction, Dr Adam Hargreaves total beneficial interest in
the Company is 175,379,305 Ordinary Shares, representing approximately 6.50%
of the Company's issued share capital.

 

The following disclosures are made in accordance with the requirements of the
UK Market Abuse Regulation and provide detail in relation to the purchase of
ordinary shares by directors and other PDMRs in the Company.

 

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Adam Hargreaves (Pathcelerate Limited)

 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Aptamer Group plc

 b)   LEI                                                          213800Y4XGH3WJNBE686

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BNRRP542

 b)   Nature of the transaction                                    Purchase of shares

 c)   Price(s) and volume(s)                                       Price 1p

                                                                   Volume 5,000,000
 d)   Aggregated information

      - Aggregated volume                                          5,000,000
      - Price                                                      1p

 e)   Date of the transaction                                      8 September 2025

 f)   Place of the transaction                                     London Stock Exchange

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHLPMRTMTAMBJA